LOS ANGELES, July 24, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.
What Is The Investigation About?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.
During the associated earnings call, management disclosed “profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier” and that “[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue.”
On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.
On July 23, 2026, the Company announced its Chief Financial Officer, Jay Saccaro, will step down from his role, and the Company will appoint an interim CFO while it searches for a permanent replacement.
Contact Us To Participate or Learn More:
If you purchased GE HealthCare securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: [email protected]
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz
310-914-5007 [email protected]
www.frankcruzlaw.com
LOS ANGELES, July 24, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.
During the associated earnings call, management disclosed “profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier” and that “[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue.”
On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.
On July 23, 2026, the Company announced its Chief Financial Officer, Jay Saccaro, will step down from his role, and the Company will appoint an interim CFO while it searches for a permanent replacement.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding GE HealthCare should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].
About Glancy Prongay Wolke & Rotter LLP
GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm’s recent successes, GPWR was named one of Law360’s Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
Key Takeaways GEHC is expected to post healthy Q2 revenue growth, backed by imaging, diagnostics, and services demand.GEHC faces margin pressure from inflation, freight, tariffs, and higher input costs despite pricing actions.GEHC expects stronger second-half performance as efficiencies, pricing, and new products gain traction. GE HealthCare Technologies Inc. (GEHC - Free Report) is scheduled to report second-quarter 2026 results on July 29, before market open.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of 99 cents missed the Zacks Consensus Estimate by 7.48%. The company beat on earnings in three of the trailing four quarters and missed once, delivering an average surprise of 2.90%.
Let’s check out the factors that might have shaped GEHC’s performance prior to the announcement.
Factors Likely to Have Driven GEHC’s Q2 PerformanceGE HealthCare is expected to have delivered another quarter of healthy revenue growth, supported by resilient global demand for imaging equipment, continued strength in Pharmaceutical Diagnostics (PDx), and robust services performance. On its first-quarter earnings call, management had maintained its full-year organic revenue growth outlook of 3-4%, citing healthy order trends, a record $21.8 billion backlog, strong book-to-bill, and improving commercial execution despite a cautious view on China.
However, profitability is likely to have remained under pressure from elevated inflation in memory chips, freight, oil and commodity costs, with management already guiding for low-single-digit adjusted EPS decline in the second quarter before improvement in the second half.
Following the organizational restructuring, the newly created Advanced Imaging Solutions business is likely to have benefited from sustained demand for CT, X-ray, ultrasound and visualization products. Imaging demand should have been supported by Revolution Vibe cardiac CT systems, while Advanced Visualization Solutions likely continued to benefit from adoption of products, such as Vivid Pioneer and other AI-enabled platforms. Although Photonova Spectra photon-counting CT generated encouraging customer interest after regulatory approvals, revenue contribution is unlikely before 2027 due to typical installation timelines.
Pharmaceutical Diagnostics is likely to have remained the company's strongest-performing business. Continued growth in contrast media, radiopharmaceuticals and molecular imaging, along with accelerating Flyrcado adoption and increasing Vizamyl demand driven by Alzheimer's imaging, likely supported another solid quarter. However, planned investments in the radiopharmaceutical pipeline and integration of recent acquisitions may have weighed on margin expansion.
Patient Care Solutions likely remained the weakest segment, although management expects gradual improvement later in the year as large monitoring installations convert from backlog and the premium anesthesia platform approaches regulatory clearance. Lower first-half volume and ongoing tariff-related costs probably continued to weigh on segment profitability.
On the margin front, the second quarter is expected to represent the peak impact from inflationary input costs, including memory chips and freight, while pricing actions and cost mitigation initiatives are likely to have provided only limited near-term relief because much of the second-quarter revenues probably originated from existing backlog. Adjusted EBIT margin and EPS are expected to have remained pressured, with a stronger recovery anticipated during the second half as pricing actions, operating efficiencies and new product momentum begin to offset inflationary pressures.
GEHC’s Estimate PictureFor second-quarter 2026, the Zacks Consensus Estimate for revenues is pegged at $5.25 billion, implying an improvement of 5% from the prior-year quarter’s reported figure.
The consensus estimate for EPS is pegged at $1.04, indicating a decrease of 1.9% from the prior-year period’s reported number.
What Our Model Suggests for GE HealthCarePer our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you will see below.
Earnings ESP: GE HealthCare has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank stocks here.
GEHC’s Share Price PerformanceSo far this year, GE HealthCare’s shares have lost 24.4% compared with the industry’s 22.5% decline. The S&P 500 has gained 9.2% during the said period.
Image Source: Zacks Investment Research
Stocks Worth a LookHere are some stocks from broader medical sector worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Aug. 11. You can see the complete list of today’s Zacks #1 Rankstocks here.
CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates an improvement of 16.4% from the year-ago reported figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank of 2 at present. The company is scheduled to release second-quarter 2026 results on Aug. 4.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.74%. The Zacks Consensus Estimate for HSIC’s second-quarter EPS implies an improvement of 10.9% from the year-ago reported figure.
Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank of 3 at present.
A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS reflects an improvement of 8% from the year-ago reported figure.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.Contact the Law Offices of Howard G. Smith to di.
Law Offices of Howard G. Smith continues its investigation on behalf of GE HealthCare Technologies Inc. (âGE HealthCareâ or the âCompanyâ) (NASDAQ: [url
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that Jay Saccaro will step down as Vice President and Chief Financial Officer for an expanded role outside of the medical technology industry. The Company has appointed George Newcomb, currently Controller and Chief Accounting Officer, as interim Chief Financial Officer. Mr. Saccaro will remain with the Company through August 14, 2026, and work together with Mr. Newcomb to ensure a smooth transition. GE HealthCare has commen.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On April 29, 2026, GE HealthCare repor.
The logo of GE Healthcare is seen on their plant in the IDA (Industrial Development Agency) estate, in Carrigtwohill, County Cork, Ireland March 28, 2025. REUTERS/Clodagh Kilcoyne Purchase Licensing Rights, opens new tab
CompaniesJuly 23 (Reuters) - GE HealthCare's (GEHC.O), opens new tab Chief Financial Officer Jay Saccaro will step down from his role to pursue an opportunity outside the medical technology industry, the company said on Thursday, and also reported preliminary second-quarter results.
The medical device maker named its current controller and chief accounting officer George Newcomb as interim CFO while it looks for a permanent replacement. Saccaro will remain with the company through August 14 to help with the handover.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Finance leadership reshuffles are taking place across the broader healthcare industry. Pfizer (PFE.N), opens new tab named an interim finance chief in June after Dave Denton announced his departure, and Baxter International (BAX.N), opens new tab appointed an interim CFO in March following Joel Grade's exit.
GE HealthCare said it expects second-quarter revenue to increase 5.7% from a year earlier, or 3.5% on an organic basis, while it reaffirmed its full-year forecast.
Quarterly diluted and adjusted earnings are expected to come in higher than a year ago and above what the company had forecast earlier, GE HealthCare said.
The Chicago-based firm previously lowered its full-year profit forecast when it reported first-quarter results, citing persistent inflation in memory-chip, oil and freight costs as well as tariff-related pressures stemming from the Middle East conflict.
Newcomb brings more than three decades of finance experience to the interim role, the company said. He has been its controller since 2016 and took on the chief accounting officer position when the firm spun off from General Electric in 2023.
Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Pooja Desai
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Key Takeaways GEHC's MIM Anyware enables secure, browser-based access to imaging data without local software installation.The platform supports real-time collaboration across oncology workflows, referrals and treatment planning.GE HealthCare also enhanced MIM Maestro and Contour ProtegeAI 2.0 with dose and AI tools. GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced the launch of MIM Anyware, a web-based remote access platform designed to provide secure, healthcare system-controlled access to imaging data and the company's MIM software portfolio. The platform gives authorized users access to MIM software applications from virtually any location through a web browser without needing local software installation. The platform aims to improve collaboration, streamline imaging workflows and support faster clinical decision-making.
Per management, research has demonstrated that effective collaboration among multidisciplinary teams is essential to deliver coordinated, patient-centered care. MIM Anyware was developed to transform how clinicians interact with medical imaging data in virtual settings. By providing secure browser-based access to imaging data and MIM's advanced analysis tools, the platform is intended to help clinicians to focus more on patient care.
Likely Trend of GEHC Stock Following the NewsFollowing the announcement, GEHC shares dropped 0.4% at yesterday’s close. Year to date, the stock has lost 23.4% compared with the industry’s 21.1% decline. However, the S&P 500 has risen 8.7% in the same timeframe.
GE HealthCare's launch of MIM Anyware is expected to strengthen its position in the cloud medical imaging platform market by expanding secure, browser-based access to imaging data and enabling real-time clinical collaboration across care teams. The platform's support for remote workflows, oncology applications and vendor-neutral interoperability aligns with the growing demand for cloud-enabled imaging solutions. This innovation is likely to increase customer adoption of GE HealthCare's portfolio of MIM software solutions.
GEHC currently has a market capitalization of $28.69 billion.
Image Source: Zacks Investment Research
More on MIM AnywareAs healthcare providers manage large volumes of complex imaging data, traditional remote access solutions often struggle with siloed workstations, IT infrastructure requirements and compatibility with modern imaging environments. MIM Anyware overcomes these challenges by ensuring secure, high-performance remote access for physicians, physicists, dosimetrists and other clinicians to work together within the same MIM session. Teams can collaboratively review image registrations, perform routine clinical processing, deploy workflows and evaluate dose information in real time while improving cross-functional collaboration and workflow efficiency.
The platform is much more valuable in cancer care, where treatment planning requires coordination among multidisciplinary teams. MIM Anyware supports radiation oncology workflows by facilitating consultations, referrals, tumor board discussions, clinician education and collaborative treatment planning.
Alongside MIM Anyware, GEHC continues to improve its MIM software portfolio with solutions such as MIM Maestro and MIM Contour ProtégéAI+ 2.0. MIM Maestro now features a reirradiation and composite dose assessment workflow that allows visualization of prior treatment doses on current anatomy, accounts for radiobiological effects and evaluates multiple treatment strategies using rigid or deformable image registration within a unified workflow.
Meanwhile, MIM Contour ProtégéAI+ 2.0 expands the company's AI-powered auto-contouring capabilities with new Magnetic Resonance Brain models and an enhanced Computed Tomography Male Pelvis model, improving contouring accuracy across key anatomical regions.
Together, the vendor-neutral MIM software portfolio supports clinical applications across radiation oncology, radiology, nuclear medicine, theranostics, interventional radiology and urology.
Industry Prospects Favoring the MarketGoing by the data provided by Research and Markets, the cloud medical imaging platform market was valued at $3.59 billion in 2025 and is projected to grow from $4.2 billion in 2026 to $7.86 billion by 2030, at a CAGR of 16.9% from 2026 to 2030.
Factors like growing implementation of AI-enabled imaging tools, increasing migration toward hybrid cloud deployment models, rising demand for multi-facility image sharing and collaboration, expansion of healthcare digitalization initiatives in emerging economies and increasing focus on workflow automation in radiology departments are boosting the market’s growth.
Other NewsRecently, GEHC announced a new research collaboration with Mayo Clinic to advance personalized cancer treatment through the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) study. The initiative will evaluate whether imaging, blood-based biomarkers and clinical data can help tailor radioligand therapy for patients with advanced prostate cancer, supporting more adaptive treatment decisions and expanding the use of theranostics.
GEHC’s Zacks Rank & Key PicksCurrently, GEHC has a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
West Pharmaceutical, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.
Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the introduction of MIM Anyware™, a remote access platform that provides secure, healthcare system-controlled access to imaging data through a web browser without requiring local software installation. By enabling authorized users to access MIM software applications from virtually any location, MIM Anyware is designed to support collaboration across departments and clinical decision-making. Today, healthcare systems are mana.
Key Takeaways GEHC's $500M alliance will deploy 1,300-plus technologies across Catholic Health over 10 years.GEHC may gain recurring revenues from equipment, maintenance, digital tools and lifecycle services.Half the equipment is expected within three years, with initial deployments beginning within months. GE HealthCare (GEHC - Free Report) recently announced a 10-year strategic Care Alliance with Catholic Health, valued at approximately $500 million. The partnership will involve the deployment of more than 1,300 pieces of technology across Catholic Health’s hospitals and ambulatory locations, spanning advanced imaging, precision diagnostics, AI-enabled technologies, digital and cloud solutions, as well as comprehensive service support.
From an investor’s perspective, the long-term alliance is likely to strengthen GE HealthCare’s recurring service and digital revenue opportunities while expanding the adoption of its AI-enabled imaging and diagnostic solutions. The deal also highlights GEHC’s ability to secure large-scale, enterprise-wide partnerships with leading healthcare systems, potentially supporting its growth prospects and strengthening position in the evolving precision care and healthcare technology markets.
Likely Trend of GEHC Stock Following the NewsShares of GEHC have gained approximately 4% since the announcement yesterday. In the year-to-date period, shares of the company have lost 19.9% compared with the industry’s 23.7% decline. The S&P 500 increased 10.9% in the same time frame.
The alliance is likely to benefit GE HealthCare’s long-term business by strengthening its presence across Catholic Health’s extensive care network and creating a steady stream of revenues from equipment deployment, maintenance, digital solutions and lifecycle services over the 10-year term. The planned addition of more than 1,300 pieces of technology, coupled with the multivendor service agreement covering more than 40 sites, should support recurring revenues and deepen customer engagement.
Moreover, broader adoption of the AI-enabled imaging, cloud and software solutions could accelerate GEHC’s shift toward higher-value digital offerings while showcasing its ability to secure large-scale, enterprise-wide partnerships. The deal may also serve as a reference model for similar long-term Care Alliances with other health systems, supporting GEHC’s growth prospects and competitive position over the long run.
GEHC currently has a market capitalization of $28.75 billion.
Image Source: Zacks Investment Research
More on the NewsUnder the Care Alliance, GEHC will support system-wide technology modernization across Catholic Health’s key service lines, including cardiology, oncology, neurology and women’s health. The initiative will expand advanced cardiac imaging across outpatient and ambulatory sites, while the addition of MR, CT and PET technologies equipped with on-device AI solutions is aimed at reducing delays between diagnostic imaging and oncology treatment.
Catholic Health also plans to expand nuclear medicine capabilities at St. Francis Hospital & Heart Center and Good Samaritan University Hospital, deploy hundreds of ultrasound systems to improve departmental efficiency and point-of-care decision-making, and enhance OB/GYN and maternal fetal medicine capabilities.
Approximately 50% of the planned equipment additions are expected to reach Catholic Health’s clinical sites within the first three years of the agreement, with patients likely to begin seeing benefits during the first year. Initial deployments, expected within months, include contrast-enhanced mammography to expand access to breast imaging and biopsy services, broader diagnostic imaging capabilities across multiple modalities and upgraded maternal-infant care monitoring technologies at Good Samaritan University Hospital.
Over the course of the alliance, expanded capabilities will be introduced at six Catholic Health hospitals and 36 other sites, spanning CT, PET/CT, nuclear medicine, MR, mammography, X-ray, surgery, ultrasound, women’s health, anesthesia, diagnostic cardiology and maternal infant care. The agreement’s unitary payment structure and accelerators are also expected to generate capital savings compared with traditional equipment-purchasing models, potentially allowing Catholic Health to reinvest in technology modernization, patient access and clinical program expansion.
Beyond equipment deployment, the alliance includes a 10-year multivendor service agreement covering more than 40 sites, with imaging and biomedical maintenance, fleet management, education and training. GEHC will also deploy AI, cloud and software solutions, including Imaging 360, to streamline radiology workflows and improve operational efficiency. The partnership builds on Catholic Health’s adoption of GEHC’s PET imaging agent Flyrcado. In April 2025, St. Francis Hospital became the first U.S. site to conduct an exercise stress PET myocardial perfusion imaging study using Flyrcado.
Favorable Industry Prospect for GEHCGoing by the data provided by Grand View Research, the global medical imaging market size was valued at $43.5 billion in 2025 and is projected to grow from $45.5 billion in 2026 to $64.7 billion by 2033, at a CAGR of 5.1% from 2026 to 2033.
The growing prevalence of chronic diseases, rising geriatric population and increasing demand for early diagnosis are expected to drive market growth. Continued investments, product innovations and advancements in AI-enabled and point-of-care medical imaging technologies should further support industry expansion.
Recent Development by GEHCRecently, GEHC announced a new research collaboration with Mayo Clinic to advance personalized cancer treatment through the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) study. The initiative will evaluate whether imaging, blood-based biomarkers and clinical data can help tailor radioligand therapy for patients with advanced prostate cancer, supporting more adaptive treatment decisions and expanding the use of theranostics.
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported first-quarter 2026 earnings per share of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
ROCKVILLE CENTRE, N.Y.--(BUSINESS WIRE)--Catholic Health, an integrated health system located on Long Island, NY, and GE HealthCare (Nasdaq: GEHC) announced today a 10-year strategic partnership, known as a Care Alliance, valued at approximately $500 million, to help expand access to advanced imaging, precision diagnostics and AI-enabled technology across Catholic Health in support of innovative, compassionate and patient-centered care. This will be one of the largest Care Alliances between GE HealthCare and a leading healthcare system in the United States to date; spanning equipment, service, digital solutions, cloud solutions and AI-enabled technologies.
The Care Alliance centers on system-wide technology and equipment modernization across key Catholic Health service lines, including cardiology, oncology, neurology, and women’s health. Through this modernization, Catholic Health aims to:
Expand Catholic Health’s renowned cardiology practice by extending advanced cardiac imaging to multiple outpatient and ambulatory sites, helping improve access to high-quality cardiac services closer to home. Reduce delays in the oncology care journey by adding MR, CT, and PET technologies equipped with on-device AI solutions, with the goal of decreasing the time from diagnostic imaging to treatment. Expand nuclear medicine capabilities at Catholic Health’s St. Francis Hospital & Heart Center® and Good Samaritan University Hospital flagship locations to enhance diagnostic confidence in oncology. Add hundreds of ultrasound systems to help increase department efficiency and support clinician confidence at the point of care, including at the bedside. Enhance women's health with expanded capabilities in OB/GYN and maternal fetal medicine. A unique aspect of the Care Alliance is an embedded cardiovascular scientist that can work directly with Catholic Health clinicians to help highlight physician perspectives, clinical insights and patient care needs, potentially informing future equipment and technology considerations.
“This Care Alliance represents an important investment in the future of health care on Long Island and reflects Catholic Health’s commitment to innovating in ways that improve how care is delivered,” said Gary Havican, Interim President and CEO and Chief Operating Officer of Catholic Health. “By combining Catholic Health’s clinical expertise and commitment to compassionate, high-quality care with GE HealthCare’s advanced technology, AI-driven tools, and digital capabilities, we are enhancing our ability to deliver precision care, expand access to specialized services closer to home, and create a more seamless experience for patients and clinicians. The partnership also gives our physicians and care teams a meaningful voice in shaping the future of care so innovation is guided by real clinical and patient needs.”
As part of the 10-year Care Alliance, approximately 50% of equipment additions will arrive at Catholic Health clinical sites during the first three years of the agreement. The agreement is also expected to generate capital savings compared with traditional equipment purchasing approaches thanks to unitary payments and accelerators, which can allow Catholic Health to reinvest resources in technology modernization, expanded patient access and clinical program growth.
For patients, the partnership is designed to have a tangible impact on their clinical experience. AI-enabled tools, standardized equipment and more consistent workflows can help Catholic Health to increase capacity, reduce delays in diagnosis and treatment, improve appointment availability, and bring specialized services — including cardiology, neurology, women’s health and cancer care — closer to home.
Patients may begin to see benefits during the first year of the agreement with equipment additions expected to arrive within months, including contrast-enhanced mammography to improve access to breast imaging and biopsy services; expanded diagnostic imaging capabilities across multiple modalities; and upgraded maternal-infant care monitoring technologies at Good Samaritan University Hospital.
Clinicians will also benefit from enhanced operational support and ongoing collaboration with GE HealthCare experts to help optimize workflows, strengthen clinical decision-making and support innovation.
Beyond equipment additions and service line expansion, the Care Alliance includes comprehensive imaging, biomedical maintenance, and service support. A 10-year, multivendor service agreement will cover delivery and maintenance of equipment across 40+ sites, including lifecycle and fleet management, as well as comprehensive education and training. The agreement is designed to support Catholic Health as it maximizes uptime, boosts asset utilization, lowers lifecycle costs, increases operational efficiency, and enhances patient care. This service component helps distinguish the Care Alliance from a traditional equipment agreement, positioning GE HealthCare as a long-term partner in supporting equipment performance and reliability across the system.
The Care Alliance will also emphasize AI, cloud, and software solutions designed to deliver actionable insights and drive operational efficiency. Digital solutions included in the Care Alliance aim to reduce manual tasks, ease cognitive load for clinicians, improve clarity for patients, and create a more seamless clinical environment. One example is Imaging 360, a cloud-based radiology operations platform that unifies radiology workflows, centralizes performance insights, and enables remote scanning support. By providing a system-wide view of imaging operations, it can help multi-site health systems improve efficiency, patient access, and care consistency.
“This Care Alliance with Catholic Health is grounded in deep collaboration to expand access and advance high-quality care across Long Island,” said Rachel Gilbreath, region president, East, U.S. and Canada at GE HealthCare. “Over the next decade, we will work side-by-side to implement innovative technology and processes across the enterprise, integrate AI, cloud, and software solutions, and support clinical excellence, including cardiology, to position Catholic Health to improve outcomes and operational performance. Together, we are aligning people, process, and technology to deliver measurable impact for patients and clinicians.”
Over the course of the Care Alliance, Catholic Health will add expanded capabilities and service lines at St. Francis Hospital & Heart Center®, St. Charles Hospital, Good Samaritan University Hospital, St. Joseph Hospital, St. Catherine of Siena Hospital, and Mercy Hospital, as well as 36 other sites. Equipment will span modalities including CT, PET/CT, nuclear medicine, MR, mammography, X-ray, surgery, ultrasound, women’s health, anesthesia, diagnostic cardiology, and maternal infant care.
Catholic Health and GE HealthCare relationship
Outside of this agreement, Catholic Health and GE HealthCare have a history of working together on precision care capabilities, including Catholic Health’s early adoption of GE HealthCare’s proprietary PET agent Flyrcado™ (flurpiridaz F 18), which supports greater diagnostic confidence and more personalized care planning. In April 2025, St. Francis Hospital & Heart Center® was the first U.S. site to perform an exercise stress PET myocardial perfusion imaging study using GE HealthCare’s Flyrcado™ (flurpiridaz F 18).
For more information about GE HealthCare’s Care Alliances, visit: https://info.gehealthcare.com/carealliance
About Catholic Health
Catholic Health is an integrated system encompassing some of the region’s finest health and human services agencies. The health system has over 17,000 employees, six acute care hospitals, three nursing homes, a home health service, hospice and a network of physician practices. Under the sponsorship of the Diocese of Rockville Centre, Catholic Health serves hundreds of thousands of Long Islanders each year, providing care that extends from the beginning of life to helping people live their final years in comfort, grace and dignity. For more information, visit: https://www.catholichealthli.org.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.
Important Safety Information and Usage of Flyrcado™ (flurpiridaz F 18) injection
FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION) ™ (flurpiridaz F 18) injection, for intravenous use important safety information
Indications and Usage
FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Contraindications
None
Warnings and Precautions
· Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent’s prescribing information.
· Radiation risks: FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.
Adverse Reactions
· Most common adverse reactions occurring during FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.
Use in Specific Populations
· Pregnancy
There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION administration to a pregnant woman, inform the patient
about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure.
FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION contains ethanol (a maximum daily dose of 337 mg anhydrous ethanol). If considering FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes associated with ethanol exposure during pregnancy.
· Lactation
Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION administration.
· Pediatric Use
Safety and effectiveness of FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION in pediatric patients have not been established.
To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at [email protected] or FDA at 800-FDA-1088 or www.fda.gov/medwatch
For full prescribing information, click here. For important safety information, please click here.
Zámořské akciové trhy během dnešního obchodování posílily, k čemuž přispěla nečekaně nízká čísla o červnové inflaci v USA, která zmírnila obavy z dalšího zvyšování úrokových sazeb ze strany Fedu. Širší index S&P 500 vzrostl o 0,38 % na 7543,86 bodu a technologický Nasdaq Composite si připsal 0,9 % na 26107,01 bodu, zatímco index Dow Jones zakončil se ziskem 0,02 % na hodnotě 52508,27 bodu. Pozitivní náladu na trhu podpořily také solidní hospodářské výsledky velkých bank na začátku nové výsledkové sezóny.
Z jednotlivých odvětví indexu S&P 500 zaznamenaly nejvýraznější růst informační technologie o 1,3 %, následované komunikačními službami, které přidaly 1,1 %, a finančním sektorem se ziskem 0,4 %. Naopak nejvíce oslabila zdravotní péče, která odepsala 1,9 %. V červených číslech skončila také nezbytná spotřeba se ztrátou 1,4 % a reality, které klesly o 0,4 %.
Mezi nejúspěšnější tituly dne se zařadila kyberbezpečnostní společnost Crowdstrike Holdings (CRWD) s nárůstem o 12 %. Výrazně posílila také investiční banka Goldman Sachs Group (GS) o 9,0 %, prodejce aut Carvana (CVNA) o 8,3 %, Palo Alto Networks (PANW) o 6,8 % a Monolithic Power Systems (MPWR) se ziskem 7,1 %. Na druhé straně po slabších kvartálních tržbách prudce propadla společnost IBM (IBM), která odepsala 25 %. Nedařilo se ani společnosti Biogen (BIIB) se ztrátou 8,2 %, HCA Healthcare (HCA) s poklesem o 7,0 %, Intuitive Surgical (ISRG) o 6,8 % a GE HealthCare Technologies (GEHC), která oslabila o 6,1 %.
Na komoditním trhu rostla severoamerická lehká ropa WTI o 1,9 % na 79,65 dolaru za barel a spotové zlato posílilo o 1,3 % na 4054,53 dolaru za unci. Americký dolar pod vlivem inflačních dat oslabil. Euro vůči němu vzrostlo o 0,4 % na 1,1424 dolaru a britská libra si připsala 0,3 % na 1,3383 dolaru, zatímco japonský jen posílil o 0,1 % na 162,19 jenu za dolar. Výnosy desetiletých američních vládních dluhopisů v reakci na nižší inflaci klesly o čtyři bazické body na 4,58 %. Bitcoin zaznamenal nárůst o 3,9 % na 64554,91 dolaru.
Index Dow Jones +0,02 % na 52508,27 b.
S&P 500 +0,38 % na 7543,86 b.
Nasdaq Composite +0,9 % na 26107,01 b.
Index S&P 500 +0,38 % na 7543,86 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Informační technologie +1,3 % Zdravotní péče -1,9 % Komunikační služby +1,1 % Nezbytná spotřeba -1,4 % Energie +0,4 % Reality -0,4 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Crowdstrike Holdings (CRWD) +12 % IBM (IBM) -25 % Goldman Sachs Group (GS) +9,0 % Biogen (BIIB) -8,2 % Carvana (CVNA) +8,3 % HCA Healthcare (HCA) -7,0 % Dell Technologies (DELL) +7,1 % Intuitive Surgical (ISRG) -6,8 % Palo Alto Networks (PANW) +6,8 % Stryker Corp (SYK) -6,1 %
Daniel Marván
Fio banka, a.s.
Prohlášení
Americké akciové trhy během probíhajícího obchodování převážně rostou, k čemuž přispívají mírnější data o americké inflaci, která oslabují obavy z brzkého zvyšování úrokových sazeb.
Zatímco technologický Nasdaq Composite posiluje o 1,01 % na 26134,09 bodu a širší S&P 500 si připisuje 0,4 % na úroveň 7545,34 bodu, index Dow Jones mírně ztrácí 0,14 % na 52422,92 bodu. Dobrou náladu na trhu podporují solidní výsledky velkých bank na začátku výsledkové sezóny a oživení u výrobců čipů, a to i přes prudký pád akcií International Business Machines Corp (IBM).
Mezi jednotlivými odvětvími indexu S&P 500 vykazují nejsilnější výkon informační technologie s růstem o 1,4 %, následované komunikačními službami, které si připisují 1 % a základními materiály s drobným ziskem 0,2 %. Naopak největší ztráty utrpěla zdravotní péče, která odepisuje 1,7 %. Oslabuje také nezbytná spotřeba o 1,1 % a reality, které klesají o 0,5 %.
V čele růstu stojí společnost Crowdstrike Holdings (CRWD), jejíž akcie posilují o 11 %. Výrazně se daří také Monolithic Power Systems (MPWR) a Goldman Sachs Group (GS), které shodně připisují 7,7 %. Dobře si vede také Dell Technologies (DELL) o 7,2 % a Palo Alto Networks (PANW) s růstem o 6,8 %. Na druhé straně zažívá propad o 25 % společnost IBM (IBM) kvůli slabším tržbám. Výrazně oslabují také HCA Healthcare (HCA) o 7,0 %, GE HealthCare Technologies (GEHC) o 6,7 %, Biogen (BIIB) o 6,6 % a Intuitive Surgical (ISRG) se ztrátou 5,8 %.
Nižší inflační tlaky tlačí dolů výnosy desetiletých amerických vládních dluhopisů, které klesají o čtyři bazické body na 4,58 %. Americký dolar v reakci na data oslabuje, takže euro vůči němu zpevňuje o 0,4 % na 1,1427 dolaru a britská libra posiluje o 0,2 % na 1,3381 dolaru, přičemž japonský jen roste rovněž o 0,2 % na 162,18 jenu za dolar. Na komoditním trhu se daří ropě i drahým kovům. Severoamerická lehká ropa WTI přidává 1,3 % na 79,12 dolaru za barel a spotové zlato roste o 1,4 % na 4058,60 dolaru za unci. V zelených číslech se pohybuje také Bitcoin, který posiluje o 3,9 % na 64556,63 dolaru.
Index Dow Jones -0,14 % na 52422,92 b.
S&P 500 +0,4 % na 7545,34 b.
Nasdaq Composite +1,01 % na 26134,09 b.
Index S&P 500 +0,4 % na 7545,34 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Informační technologie +1,4 % Zdravotní péče -1,7 % Komunikační služby +1 % Nezbytná spotřeba -1,1 % Základní materiály +0,2 % Reality -0,5 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Crowdstrike Holdings (CRWD) +11 % IBM (IBM) -25 % Monolithic Power Systems (MPWR) +7,7 % HCA Healthcare (HCA) -7,0 % Goldman Sachs Group (GS) +7,7 % GE HealthCare Technologies (GEHC) -6,7 % Dell Technologies (DELL) +7,2 % Biogen (BIIB) -6,6 % Palo Alto Networks (PANW) +6,8 % Intuitive Surgical (ISRG) -5,8 %
Daniel Marván, Fio banka, a.s.
Investors in GE HealthCare Technologies Inc. (GEHC - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Sept. 18, 2026 $35.00 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for GE HealthCare shares, but what is the fundamental picture for the company? Currently, GE HealthCare is a Zacks Rank #4 (Sell) in the Medical - Products industry that ranks in the Bottom 19% of our Zacks Industry Rank. Over the last 60 days, one analyst has increased the earnings estimate for the current quarter, while none have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1.23 per share to $1.25 in that period.
Given the way analysts feel about GE HealthCare right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Key Takeaways GE HealthCare is collaborating with Mayo Clinic to advance personalized cancer theranostics.The MI-BET study will assess whether imaging, biomarkers and data can tailor RLT cycles.Researchers will use StarGuide SPECT/CT and MIM LesionID Pro to monitor tumor response. GE HealthCare (GEHC - Free Report) has announced a new research collaboration with Mayo Clinic to advance personalized cancer treatment through the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) study. The initiative will evaluate whether imaging, blood-based biomarkers and clinical data can help tailor radioligand therapy for patients with advanced prostate cancer, supporting more adaptive treatment decisions and expanding the use of theranostics.
From an investor's perspective, the collaboration reinforces GE HealthCare's growing focus on precision oncology and theranostics, a rapidly evolving area of cancer care. By leveraging its StarGuide SPECT/CT platform and MIM Software's advanced imaging capabilities in a high-profile clinical research setting, the company stands to strengthen the clinical validation and long-term adoption of its imaging technologies. If the study generates favorable evidence, it could enhance GE HealthCare's competitive positioning in molecular imaging, support future demand for its theranostics portfolio and create additional growth opportunities in the expanding precision medicine market.
Likely Trend of GEHC Stock Following the NewsShares of GEHC have traded flat since the announcement on July 8. In the year-to-date period, shares of the company have lost 21.2% compared with the industry’s 20.4% decline. The S&P 500 increased 9.9% in the same time frame.
In the long term, the collaboration is expected to strengthen GE HealthCare's position in the fast-growing theranostics and precision oncology markets by generating real-world clinical evidence for its advanced molecular imaging technologies. Positive findings from the MI-BET study could accelerate the adoption of the company's StarGuide SPECT/CT platform and MIM Software solutions across healthcare systems, while reinforcing GE HealthCare's role as a strategic partner in data-driven cancer care.
The collaboration also enhances the company's innovation pipeline, supports the development of imaging biomarkers and adaptive treatment workflows and could create opportunities for broader commercial adoption as theranostics becomes an increasingly important component of personalized oncology.
GEHC currently has a market capitalization of $29.52 billion.
Image Source: Zacks Investment Research
More on the NewsThe MI-BET study is designed to challenge the conventional approach of administering a fixed number of radioligand therapy cycles by evaluating whether treatment can instead be tailored to an individual patient's response. Using GE HealthCare's StarGuide SPECT/CT system alongside MIM Software's MIM LesionID Pro, researchers will monitor tumor response throughout treatment.
By integrating imaging findings with clinical outcomes and blood-based biomarkers, the study aims to determine whether these data-driven insights can guide decisions such as pausing or adapting therapy based on disease progression. Researchers also intend to identify predictive biomarkers that could help physicians anticipate patient response earlier in the treatment journey, enabling more personalized care.
The collaboration is also focused on expanding access to advanced theranostics by encouraging broader patient participation through community outreach, partnerships with advocacy organizations and the use of telemedicine to reduce barriers to enrollment. According to Mayo Clinic, the initiative reflects a broader shift toward adaptive, patient-specific cancer care models that seek to optimize treatment effectiveness while minimizing unnecessary therapy. In addition to evaluating treatment duration, the study will investigate novel imaging biomarkers and data-driven approaches that could further enhance clinical decision-making and improve patient outcomes.
The research will be conducted at Mayo Clinic's Rochester, MN, campus, combining the organization’s expertise in clinical practice, research and product development. As part of the collaboration, Mayo Clinic has also become the first U.S. site to investigate GE HealthCare's next-generation StarGuide GX SPECT/CT technology, which is designed to improve tumor assessment precision while potentially reducing scan times. Although the StarGuide GX system has received CE Mark certification and is not yet approved for commercial sale in the United States, the collaboration underscores GE HealthCare's commitment to advancing next-generation molecular imaging technologies and supporting the broader adoption of precision oncology solutions.
Favorable Industry Prospect for GEHCGoing by the data provided by Precedence Research, the global theranostics market size was calculated at $10.29 billion in 2025 and is predicted to increase from $11.50 billion in 2026 to approximately $31.38 billion by 2035, expanding at a CAGR of 11.8%.
The market growth is driven by the rising incidence of chronic diseases, the shift toward personalized medicine, and advances in molecular imaging and radiopharmaceuticals.
A Recent Development by GEHCRecently, GEHC announced the Allia platform upgrade pathways to help healthcare providers modernize select legacy Innova and Discovery Image Guiding Solutions systems. The initiative comes as healthcare providers face growing procedural complexity, rising patient volumes and aging imaging equipment.
The upgrades enable health systems to access the latest Allia technologies and AI-enabled workflows while preserving existing infrastructure, reducing the need for major construction and minimizing disruption to clinical operations.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
, /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. ("GE HealthCare" or the "Company") (NASDAQ: GEHC) investors concerning the Company's possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.
During the associated earnings call, management disclosed "profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier" and that "[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue."
On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding GE HealthCare should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].
About Glancy Prongay Wolke & Rotter LLP
GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm's recent successes, GPWR was named one of Law360's Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.
CHICAGO & ROCHESTER, Minn.--(BUSINESS WIRE)--GE HealthCare and Mayo Clinic today announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration, a novel theranostics study designed to explore a more personalized approach to radioligand therapy (RLT) for patients with advanced prostate cancer. This collaboration is a direct result of the 2023 Strategic Radiology Research Alliance between Mayo Clinic and GE HealthCare, aimed at transforming the experience of.
, /PRNewswire/ -- Law Offices of Howard G. Smith continues its investigation on behalf of GE HealthCare Technologies Inc. ("GE HealthCare" or the "Company") (NASDAQ: GEHC) investors concerning the Company's possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.
During the associated earnings call, management disclosed "profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier" and that "[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue."
On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.
Contact Us To Participate or Learn More:
If you purchased GE HealthCare securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will.
, /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of GE HealthCare Technologies Inc. ("GE HealthCare" or the "Company") (NASDAQ: GEHC) on behalf of investors concerning the Company's possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.
What Is The Investigation About?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.
During the associated earnings call, management disclosed "profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier" and that "[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue."
On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.
Contact Us To Participate or Learn More:
If you purchased GE HealthCare securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: [email protected]
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE The Law Offices of Frank R. Cruz, Los Angeles
CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2026 payable on August 14, 2026, to all shareholders of record as of July 24, 2026.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.
Key Takeaways GE HealthCare unveiled Allia upgrade pathways for select legacy Innova and Discovery IGS systems.The upgrades add Allia technologies and AI-enabled workflows while preserving existing infrastructure.Options include CleaRecon DL, 3DStent, OmnifyXR, Embo ASSIST AI, Medis QFR and AVVIGO . GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced Allia platform upgrade pathways to help healthcare providers modernize select legacy Innova and Discovery Image Guiding Solutions (IGS) systems. The initiative comes as healthcare providers face growing procedural complexity, rising patient volumes and aging imaging equipment.
The upgrades enable health systems to access the latest Allia technologies and AI-enabled workflows while preserving existing infrastructure, reducing the need for major construction and minimizing disruption to clinical operations.
Per management, Allia upgrade pathways reflect GEHC’s commitment to helping customers modernize on their own terms by extending the capabilities of existing systems while providing access to the latest Allia innovations and AI-enabled technologies in a less disruptive, more sustainable way.
Likely Trend of GEHC Stock Following the NewsFollowing the announcement, GEHC shares dropped 1.1% at yesterday’s closing. In the year-to-date period, the stock has lost 20.7% compared with the industry’s 21.1% decline. However, the S&P 500 has risen 8.9% in the same timeframe.
The latest Allia upgrade pathways are expected to strengthen GE HealthCare’s position in the interventional imaging market. Offering a cost-effective modernization strategy instead of full system replacements is likely to attract healthcare providers seeking to upgrade aging infrastructure. The integration of AI-powered imaging and workflow solutions could drive broader adoption of its interventional solutions and support long-term growth.
GEHC currently has a market capitalization of $29.91 billion.
Image Source: Zacks Investment Research
More on the Upgrade PathwaysThe Allia upgrade pathways provide access to several advanced imaging and workflow solutions, depending on system configuration and regulatory approvals. These include CleaRecon DL, an AI-enabled deep learning reconstruction technology that improves cone beam CT image quality by reducing streak artifacts caused by the pulsatile nature of blood flow during procedures.
The upgrades also include 3DStent, an intraprocedural 3D coronary stent visualization tool that enhances image clarity for easier interpretation, and OmnifyXR Interventional Suite, an augmented reality guidance solution that supports workflow efficiency, ergonomics and collaborative care. Embo ASSIST AI helps optimize embolization procedures, while Medis Quantitative Flow Ratio enables coronary physiology assessment without additional invasive procedures.
Healthcare providers can also access the AVVIGO+ intravascular imaging (IVUS) platform, which integrates imaging, physiology and percutaneous coronary intervention guidance to support catheterization lab procedures.
Beyond clinical capabilities, GE HealthCare is incorporating Tube Watch and OnWatch Predict service options that use AI to estimate component failure timelines, helping reduce unplanned downtime through proactive maintenance. By extending the lifespan of existing interventional suites, GE HealthCare aims to improve operational efficiency, optimize capital investments and support long-term sustainability goals.
Industry Prospects Favoring the MarketGoing by data provided by Precedence Research, the interventional radiology market is anticipated to be valued at $31.44 billion in 2026 and is expected to witness a CAGR of 4.9% through 2034.
Factors like the rising prevalence of chronic diseases such as cardiovascular, oncology and gastroenterology, etc., the growing preference for minimally invasive treatments, technological advancements in imaging and interventional devices and the expansion of healthcare infrastructure and early disease detection initiatives are driving the market’s growth.
Other NewsGE HealthCare recently announced that the FDA has granted 510(k) clearance for MIM Contour ProtegeAI+ 2.0, an AI-enabled auto-contouring software designed to support radiation therapy treatment planning. The latest version expands clinical capabilities with new Magnetic Resonance Brain and updated Computed Tomography Male Pelvis models.
The FDA clearance includes a Predetermined Change Control Plan, providing a pathway for future model updates and expansion into additional anatomical regions and imaging modalities.
Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
BrightSpring Health, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank stocks here.
BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced Allia™ platform upgrade pathways designed to help customers modernize select legacy Innova™ and Discovery™ Image Guiding Solutions (IGS) systems. These pathways provide access to Allia technologies and workflows that support efficiency and procedural decision-making while helping preserve existing infrastructure, avoid major construction work, extend interventional room lifetime, and minimize disruption to clinical operations.
As procedural complexity and patient volumes grow and installed systems age, healthcare providers are looking for flexible ways to modernize interventional environments while balancing operational, infrastructure and capital planning priorities. According to the European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry (COCIR), one-third of interventional X-ray systems in Europe are more than 10 years old, highlighting the importance of technology renewal planning to support increased access to advanced care.i
The upgrade pathways can help customers extend the value of existing systems through workflow enhancements, expanded interoperability capabilities and access to Allia innovations, while helping reduce infrastructure replacement needs and support long-term operational and sustainability goals.
“Interventional care continues to evolve rapidly, and health systems are looking for technology strategies that balance innovation, operational continuity and long-term value,” said Jyoti Gera, CEO, CardioVascular and Interventional Solutions, Advanced Imaging Solutions, GE HealthCare. “These Allia upgrade pathways reflect our commitment to helping customers modernize on their own terms by extending the capabilities of existing systems while providing access to the latest Allia innovations and AI-enabled technologies in a less disruptive, more sustainable way.”
Depending on system configuration, market availability and applicable regulatory requirements, upgrade options may provide access to capabilities and to third party solutions, including:
CleaRecon DL,ii an AI-enabled deep learning reconstruction technology designed to support CBCT image interpretation confidence by reducing streak artifacts caused by the pulsatile nature of blood flow during procedures. 3DStent,iii an intraprocedural tool for 3D visualization of the coronary stent designed to remove major stent imaging barriers and provide easy to interpret images. OmnifyXR™ Interventional Suite, an augmented reality guidance solution designed to support workflow efficiency and ergonomics and provide improved visualization and collaborative care for procedures such as prostate embolization.iv Embo ASSIST AI, an augmented guidance solution designed to optimize embolization strategies and streamline clinical workflow.v Medis Quantitative Flow Ratio®vi, a software solution, designed to assess coronary physiology in patients with coronary artery disease. AVVIGO™+ intravascular imaging (IVUS) platformvii multimodality guidance platform that enhances the IVUS and physiology experience and integrates percutaneous coronary intervention tools to support users in the catheterization lab. GE HealthCare also provides Tube Watch and/or OnWatch™ Predict service options on all upgraded systems. These options help customers proactively manage system performance and maintenance by providing an AI-poweredviii estimated lead time to failure, supporting efforts to reduce unplanned downtime.
These upgrade pathways are available in the U.S. and other countries where Allia IGS and Allia IGS Pulse systems are available for sale (and have been approved, cleared or registered by the appropriate regulatory authorities). Please contact your local GE HealthCare representative with any questions about this upgrade program. For more information on the available Allia upgrade capabilities, visit: https://www.gehealthcare.com/en-us/services/igs-upgrades.
Through GE HealthCare’s upgrade programs, customers can access technology designed to help enhance image quality, expand imaging capabilities with advanced applications, and streamline workflows across image guiding solutions, X-ray, MR and CT systems. These programs are designed to help customers unlock new value from existing systems through smart technology and AI-powered and digital solutions, while supporting productivity, operational continuity and patient-centered care.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.
i COCIR. 2023. Medical Imaging Equipment Age Profile and Density: 2023 Edition.
https://www.cocir.org/wp-content/uploads/23060_COC_X-Ray-INTERVENTIONAL-scaled.jpg.
ii CleaRecon DL, designed to be used with Allia systems, is an option in 3DXR designed to be used with Allia systems and requires AW workstation with Volume Viewer. May not be available in all countries.
iii 3DStent solution includes Allia™ system, 3DXR and Volume Viewer Innova, and requires AW workstation with Volume Viewer. These applications are sold separately. Not available for sale in all countries. 3DStent is available on Allia™ IGS 5 with 20-cm or 30-cm detector and Allia™ IGS 7 with 30-cm detector.
iv OmnifyXR™ Augmented Reality Interventional Suite is a MediView product built in collaboration with and currently exclusively available with compatible GE HealthCare systems. OmnifyXR™ is intended to be used adjunctively to standard of care imaging. Proceduralists must refer to standard of care imaging and prioritize clinical experience and/or judgment when using the OmnifyXR™ system. OmnifyXR™ is not intended to be the sole visualization for any procedure.
v Embo ASSIST AI solution includes FlightPlan for Embolization with AI Segmentation option and requires AW workstation with Volume Viewer, Volume Viewer Innova, Vision 2, VesselIQ Xpress, Autobone Xpress. These applications are sold separately.
vi Medis QFR® is a product from Medis Medical Imaging.
vii AVVIGO+ is an option of Allia IGS 3, Allia IGS 5, Allia IGS 7, Allia IGS 7 OR. AVVIGO™+ is a trademark of Boston Scientific. AVVIGO™+ is manufactured and sold by Boston Scientific and is distributed by GE HealthCare. Refer to your Boston Scientific sales representatives for more information.
viii An AI-powered deep machine learning model trained on data from installed systems, leveraging aggregated error logs, parametric data, and historical service activity on eligible systems.
Key Takeaways GE HealthCare expanded its clinical engineering services relationship with Carilion Clinic in Virginia.Carilion will implement AAMP and Encompass to improve equipment management and efficiency.Encompass will give Carilion real-time visibility into mobile medical equipment across facilities. GE HealthCare Technologies Inc. (GEHC - Free Report) recently expanded its clinical engineering services relationship with Carilion Clinic to support patient care and community health initiatives across Virginia. Under the collaboration, Carilion Clinic will implement GE HealthCare’s Advanced Asset Management Program (AAMP) and Encompass, a real-time location system (RTLS), to improve medical equipment management and operational efficiency across its healthcare network.
Per management, patient care remains at the center of GE HealthCare's priorities. The company’s long-standing collaboration with Carilion Clinic reflects a shared commitment to delivering a consistent and efficient experience for patients and caregivers across the health system's facilities. By combining advanced asset management capabilities with enhanced digital visibility, GE HealthCare aims to support Carilion's teams in delivering high-quality care to patients.
Likely Trend of GEHC Stock Following the NewsShares of GEHC have gained 1% since the announcement on Thursday. In the year-to-date period, shares of the company have fallen 20.6% compared with the industry’s 23.2% decline. However, the S&P 500 has risen 8.1% in the same timeframe.
In the long run, the expanded collaboration strengthens GEHC’s position in healthcare technology and clinical engineering services. By deepening its relationship with Carilion Clinic, GEHC gains another opportunity to demonstrate the value of its connected healthcare solutions, which could support broader adoption across health systems seeking greater efficiency and cost optimization. The agreement also aligns with the company’s strategy of integrating digital technologies and service-based offerings with its healthcare portfolio to create long-term value and recurring revenue opportunities.
GEHC currently has a market capitalization of $29.65 billion.
Image Source: Zacks Investment Research
More on the Expanded CollaborationThe collaboration includes GE HealthCare’s Advanced Asset Management Program, which is designed to optimize medical equipment throughout its lifecycle. The program focuses on improving consistency in equipment planning, deployment and support, enabling clinical and operational teams to make more informed decisions while reducing workflow burdens.
Carilion Clinic will expand the use of GE HealthCare’s Encompass web-based RTLS platform, which provides real-time visibility into mobile medical equipment across the healthcare system. The solution helps staff locate equipment efficiently, minimize downtime, reduce patient delays and improve caregiver productivity.
The collaboration also extends Encompass capabilities across Carilion’s facilities, including Roanoke Memorial Hospital’s Crystal Spring Tower. Together, GE HealthCare and Carilion continue to strengthen a partnership focused on operational excellence, clinician support and delivering high-quality care to the communities they serve across Virginia.
Industry Prospects Favoring the MarketGoing by data provided by Precedence Research, the healthcare asset management market is valued at $43.88 billion in 2026 and is expected to witness a CAGR of 26.85% through 2035.
Factors like the rising focus on operational efficiency and cost reduction, the need for better equipment tracking and inventory management, the growing pressure to improve workforce productivity and patient care, as well as accelerating healthcare digitalization, are the major drivers of the market.
Other NewsGE HealthCare recently announced that the FDA has granted 510(k) clearance for MIM Contour ProtegeAI+ 2.0, an AI-enabled auto-contouring software designed to support radiation therapy treatment planning. The latest version expands clinical capabilities with new Magnetic Resonance Brain and updated Computed Tomography Male Pelvis models.
The FDA clearance includes a Predetermined Change Control Plan, providing a pathway for future model updates and expansion into additional anatomical regions and imaging modalities.
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Biodesix, currently carrying a Zacks Rank of 2 (Buy), reported a first-quarter 2026 adjusted loss per share of 81 cents, which came narrower than the Zacks Consensus Estimate by 35.7%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.6%.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOV.
[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, today announced that it has commenced an investigation on behal
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In GE HealthCare (GEHC) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in GE HealthCare and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) --
What’s Happening:
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ:GEHC) on behalf of GE HealthCare stockholders. Our investigation concerns whether GE HealthCare has violated the federal securities laws and/or engaged in other unlawful business practices. Investigation Details:
On April 29, 2026, GE HealthCare announced its financial results for the first quarter of 2026. Among other disclosures, the Company reported adjusted earnings per share of $0.99, missing the consensus estimate of $1.05, and reduced its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00 from its prior guidance of $4.95 to $5.15. During the related earnings call, CEO Peter Arduini stated that “profitability in the first quarter was impacted by a PDx supplier issue that has since been resolved.” Following this news, the price of GE HealthCare shares fell by $9.01 per share, or approximately 13%, declining from $68.50 per share on April 28, 2026 to close at $59.49 per share on April 29, 2026. Next Steps:
If you purchased or otherwise acquired GE HealthCare shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ:GEHC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99, missing the consensus estimate of $1.05, and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15. CEO Peter Arduini said that “profitability in the first quarter was impacted by a PDx supplier issue that has since been resolved.” On this news, the price of GE HealthCare shares declined by $9.01 per share, or approximately 13%, from $68.50 per share on April 28, 2026 to close at $59.49 on April 29, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired GE HealthCare securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
The law firm of [url="]Kirby McInerney LLP[/url] continues its investigation on behalf of GE HealthCare Technologies Inc. (âGE HealthCareâ or the âCompan
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ:GEHC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99, missing the consensus estimate of $1.05, and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15. CEO Peter Arduini said that “profitability in the first quarter was impacted by a PDx supplier issue that has since been resolved.” On this news, the price of GE HealthCare shares declined by $9.01 per share, or approximately 13%, from $68.50 per share on April 28, 2026 to close at $59.49 on April 29, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired GE HealthCare securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened.
[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technolo
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.
What Is The Investigation About?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.
During the associated earnings call, management disclosed “profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier” and that “[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue.”
On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.
Contact Us To Participate or Learn More:
If you purchased GE HealthCare securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: [email protected]
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
[url="]The Law Offices of Frank R. Cruz[/url] continues its investigation of GE HealthCare Technologies Inc. (âGE HealthCareâ or the âCompanyâ) (NASDAQ:
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.
During the associated earnings call, management disclosed “profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier” and that “[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue.”
On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.
Contact Us To Participate or Learn More:
If you purchased GE HealthCare securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Key Takeaways GEHC launched a research collaboration with UW Medicine Radiology to advance CT and molecular imaging tech.Partnership aims automated workflows in cardiology, oncology and theranostics to speed clinical translation.Programs will build evidence for spectral imaging, AI protocols and oncology image-processing solutions. GE HealthCare Technologies Inc. (GEHC - Free Report) recently entered into a research collaboration with the University of Washington Department of Radiology (UW Medicine Radiology), focused on advancing computed tomography (“CT”) and molecular imaging (“MI”) technologies. The initiative aims to automate workflows across cardiology, oncology and theranostics while supporting faster clinical translation of next-generation imaging technologies.
Per management, molecular imaging and CT are converging more than ever to improve disease detection and characterization throughout the patient journey. The collaboration with UW Medicine Radiology will help to advance imaging technologies that provide more precise, actionable insights and support greater precision in diagnostic imaging innovation.
Likely Trend of GEHC Stock Following the NewsShares of GEHC have lost 0.2% since the announcement on Thursday. In the year-to-date period, shares of the company have fallen 21.7% compared with the industry’s 22.2% decline. However, the S&P 500 has risen 9.6% in the same timeframe.
In the long run, the collaboration strengthens GEHC’s position in advanced diagnostic imaging and precision medicine by deepening its 30-year relationship with UW Medicine Radiology. The partnership provides GEHC with a platform to refine and validate next-generation CT and molecular imaging technologies in real-world clinical settings, supporting broader adoption across global healthcare systems. The initiative also supports GEHC’s strategy of combining AI, automation and imaging hardware to improve workflow efficiency and deliver personalized patient care.
GEHC currently has a market capitalization of $29.22 billion.
Image Source: Zacks Investment Research
More on the Strategic CollaborationThe research collaboration between UW Medicine Radiology and GE HealthCare is focused on advancing CT, MI and theranostics to improve diagnosis, treatment and patient care. The partnership is built around two core programs aimed at accelerating innovation in imaging technologies and clinical workflows.
The CT program seeks to advance CT imaging science and clinical practice through research, collaboration and education. Key efforts include generating clinical evidence to support the adoption of spectral imaging technologies and improving CT workflows through automation and software tools that enhance efficiency for clinicians and patient experiences.
The MI and theranostics initiatives are designed to support personalized cancer care by integrating advanced diagnostic imaging, AI-enabled software and radiopharmaceuticals. The collaboration will focus on developing clinical evidence for innovative imaging protocols, applying deep learning to improve treatment planning and clinical trial matching, and creating advanced oncology imaging and image-processing solutions that enable precise, personalized care.
Industry Prospects Favoring the MarketGoing by the data provided by Mordor Intelligence, the U.S. diagnostic imaging market is valued at $10.57 billion in 2026 and is expected to witness a CAGR of 4.5% through 2031.
Factors like the AI-driven workflow and image interpretation, shift of imaging volumes to outpatient and ambulatory settings, rapid penetration of portable and handheld ultrasound/X-ray systems are driving the market’s growth.
Other NewsGE HealthCare recently announced a series of advancements in its next-generation SIGNA MR portfolio, including the FDA 510(k)-pending Sonic DL for faster AI-powered 2D imaging, the AI-enabled SIGNA One workflow ecosystem and the next-generation SIGNA Bolt 3T MRI system. The company also introduced the helium-free SIGNA Sprint with Freelium, expanded AIR Recon DL support for ZTE and Silenz imaging and launched SIGNA Studio research collaboration tools. In neuroscience, GE HealthCare announced new installations of its investigational MAGNUS head-only MR scanner at King’s College London and West China Hospital.
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Globus Medical, currently sporting a Zacks Rank #1, reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.6%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
A month has gone by since the last earnings report for GE HealthCare Technologies (GEHC - Free Report) . Shares have added about 3.3% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is GE HealthCare due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for GE HealthCare Technologies Inc. before we dive into how investors and analysts have reacted as of late.
GEHC Q1 Earnings Miss Estimates, Revenues Beat, Net Margin DeclinesGE HealthCare Technologies reported first-quarter 2026 adjusted earnings per share of 99 cents, which missed the Zacks Consensus Estimate of $1.07 by 7.5%. Also, the bottom line declined 1.9% year over year.
GAAP earnings per share in the quarter was 85 cents, down 30.9% from the year-ago level.
GEHC’s Q1 Revenue DetailsRevenues of $5.13 billion were up 7.4% year over year on a reported basis and 2.9% organically. The top line beat the Zacks Consensus Estimate by 1.5%. Total company orders increased 1.1% year over year organically. The book-to-bill was 1.07X, reflecting rising orders compared to shipments.
Revenues were supported by strong performance in the United States, EMEA and Rest of World markets, primarily across three segments — Pharmaceutical Diagnostics (PDx), Imaging and Advanced Visualization Solutions (“AVS”) — partially offset by a decline in the Patient Care Solutions segment.
GE HealthCare’s Segmental DetailsImaging
Revenues from this segment totaled $2.29 billion, up 7.4% year over year on a reported basis and 3.8% organically.
Segment EBIT was $180 million, down 9.4% year over year.
Advanced Visualization Solutions
Revenues totaled $1.34 billion, up 8.2% year over year on a reported basis and 4.4% organically.
Segment EBIT was $299 million, up 14.5% year over year.
Patient Care Solutions
Revenues amounted to $704 million, down 6.5% year over year on a reported basis and down 8.1% organically.
Segment EBIT was $10 million, down 79.8% year over year.
Pharmaceutical Diagnostics
Revenues totaled $770 million, up 21.7% year over year and 9.7% on an organic basis.
Segment EBIT was $197 million, down 3.9% year over year.
GEHC’s Q1 Margin AnalysisNet income margin was 7.6%, down 420 basis points from the prior-year level due to the unfavorable impact of tariffs, a decline in Patient Care Solutions (PCS) and the PDx supplier issue.
Cumulative cash flow from operating activities at the end of the first quarter was $290 million compared with $250 million a year ago.
GE HealthCare’s Financial PositionGEHC exited the first quarter with cash, cash equivalents and investments of $2.28 billion compared with $4.51 billion in the previous quarter.
Total assets increased to $37.12 billion from $36.91 billion on a sequential basis.
GEHC’s 2026 GuidanceGE HealthCare updated its adjusted earnings per share guidance for 2026.
The company expects organic revenue growth of 3-4% in 2026. It anticipates adjusted earnings per share to be in the range of $4.80-$5.00, implying 4.6%-9.0% year-over-year growth. However, the guidance range is down from $4.95-$5.15, as expected previously. At current tariff rates, GEHC expects a lower impact in 2026 versus 2025.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates revision.
The consensus estimate has shifted -10.79% due to these changes.
VGM ScoresAt this time, GE HealthCare has a subpar Growth Score of D, a grade with the same score on the momentum front. However, the stock has a score of B on the value side, putting it in the second quintile for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise GE HealthCare has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry PlayerGE HealthCare is part of the Zacks Medical - Products industry. Over the past month, Zimmer Biomet (ZBH - Free Report) , a stock from the same industry, has gained 0.5%. The company reported its results for the quarter ended March 2026 more than a month ago.
Zimmer reported revenues of $2.09 billion in the last reported quarter, representing a year-over-year change of +9.3%. EPS of $2.09 for the same period compares with $1.81 a year ago.
Zimmer is expected to post earnings of $1.99 per share for the current quarter, representing a year-over-year change of -3.9%. Over the last 30 days, the Zacks Consensus Estimate has changed -2.3%.
Zimmer has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.
CHICAGO--(BUSINESS WIRE)--As theranostics adoption acceleratesi and radiopharmaceutical demand grows,ii healthcare systems are under increasing pressure to scale nuclear medicine operations while improving diagnostic confidence and workflow efficiency. At the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare showcases its latest technologies and AI-enabled workflows to help support precision care across care pathways. Nuclear medicine is undergoing rap.
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for MIM Contour ProtégéAI+™ 2.0, an AI-enabled auto-contouring software to assist radiation oncology care teams with treatment planning. This can help clinicians reduce treatment planning time, enabling them to focus on delivering more timely and personalized care for patients. The FDA clearance includes a Predetermined Change Control.
Key Takeaways GEHC received FDA clearance for MIM Contour ProtegeAI 2.0 radiation planning software.GEHC's clearance includes a PCCP, enabling faster future AI model updates and expansion.GEHC said that the software automates contouring to streamline workflows and support cancer care. GE HealthCare (GEHC - Free Report) recently announced that the FDA has granted 510(k) clearance for MIM Contour ProtegeAI+ 2.0, an AI-enabled auto-contouring software designed to support radiation therapy treatment planning. The latest version expands clinical capabilities with new Magnetic Resonance Brain and updated Computed Tomography Male Pelvis models.
The clearance also includes a Predetermined Change Control Plan (PCCP), allowing GE HealthCare to introduce future AI model updates more efficiently. By automating one of the most time-intensive steps in radiation therapy planning, the technology is expected to help streamline clinical workflows, reduce planning time and support more personalized cancer care.
Likely Trend of GEHC Stock Following the NewsShares of GEHC have gained 2.9% since the announcement on Thursday. In the year-to-date period, shares of the company have lost 22.2% compared with the industry’s 25.2% decline. However, the S&P 500 has risen 10.2% during the same timeframe.
The FDA clearance strengthens GE HealthCare’s Pharmaceutical Diagnostics and Advanced Visualization portfolio within its Imaging segment by expanding its presence in the growing radiation oncology market. The addition of AI-enabled treatment planning tools enhances the company's software and digital solutions ecosystem, creating opportunities for recurring revenue, deeper customer engagement and cross-selling across imaging, oncology and workflow products.
Over the long term, faster deployment of new AI models under the approved change-control framework could support broader adoption, reinforce GE HealthCare’s competitive position in precision oncology and contribute to higher-margin software-driven growth.
GEHC currently has a market capitalization of $28.22 billion.
Image Source: Zacks Investment Research
More on the NewsMIM Contour ProtegeAI + 2.0 is an AI-enabled auto-contouring software designed to assist radiation oncology teams during treatment planning. The latest version introduces new clinical models, including a Magnetic Resonance (MR) Brain model and an updated Computed Tomography (CT) Male Pelvis model, expanding its applicability across important anatomical regions. The software helps automate contouring — a critical step in radiation therapy planning that involves identifying tumors and surrounding organs on medical images. By reducing manual effort, the technology can help clinicians accelerate treatment planning while maintaining consistency and accuracy.
A key highlight of the announcement is the FDA’s clearance of a PCCP. The framework allows GE HealthCare to implement future AI model updates and enhancements through a predefined regulatory pathway, enabling faster expansion into additional anatomical regions and imaging modalities. This flexibility is particularly important in AI-driven healthcare software, where continuous model improvements are essential to maintaining clinical relevance and performance. The clearance positions GE HealthCare to bring future innovations to customers more efficiently while remaining within regulatory requirements.
According to GE HealthCare, the underlying AI models were developed and validated using multi-institution datasets and have demonstrated contour quality comparable to, or better than, traditional approaches. Unlike many conventional auto-contouring tools, MIM Contour ProtegeAI + is designed to operate with minimal user interaction, automatically initiating contour generation and supporting automated processing of both CT and MR images. The software can export results directly into treatment planning systems or MIM Workflows, enabling seamless integration into existing clinical workflows.
As part of GE HealthCare’s broader radiation oncology ecosystem, the solution is intended to improve workflow efficiency and allow care teams to devote more time to optimizing personalized treatment plans for patients.
Industry Prospects Favoring the MarketPer a report by Grand View Research, the global radiation oncology market size was estimated at $14.03 billion in 2025 and is projected to reach $33.09 billion by 2033, expanding at a CAGR of 11.42%.
This growth is driven by the rising prevalence of cancer and increasing demand for effective, targeted treatment options.
Other NewsGE HealthCare recently announced a series of advancements in its next-generation SIGNA MR portfolio, including the FDA 510(k)-pending Sonic DL for faster AI-powered 2D imaging, the AI-enabled SIGNA One workflow ecosystem and the next-generation SIGNA Bolt 3T MRI system.
The company also introduced the helium-free SIGNA Sprint with Freelium, expanded AIR Recon DL support for ZTE and Silenz imaging and launched SIGNA Studio research collaboration tools. In neuroscience, GE HealthCare announced new installations of its investigational MAGNUS head-only MR scanner at King’s College London and West China Hospital.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
West Pharmaceutical, currently sporting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
CHICAGO--(BUSINESS WIRE)--GE HealthCare will showcase its latest enterprise imaging solutions at the Society for Imaging Informatics in Medicine (SIIM) 2026 Annual Meeting in Pittsburgh, PA.
Medical imaging departments today are under immense pressure from all sides including rising imaging volumes and increasing case complexity, while staffing shortages continue to grow. According to the American College of Radiology (ACR), radiologist workforce shortages have been identified as the biggest threat facing radiology for three consecutive years. This makes the ability to interpret studies from anywhere essential for maintaining throughput and ensuring timely diagnoses.1
GE HealthCare continues to accelerate enterprise imaging solutions with Genesis™ Radiology Workspace.2 Genesis Radiology Workspace is a next-generation solution designed to transform radiology workflows, unify the user experience, and empower radiologists with great efficiency and precision. At the center of this innovation is View, FDA 510(k)-cleared, a powerful new viewer designed to be a fast diagnostic, zero-footprint viewer – streamlining radiology workflows with the intent to help enhance patient care while being fully accessible from any location. Genesis Radiology Workspace is designed to give radiologists the freedom to read from anywhere—without sacrificing speed or accuracy. Its high-performance visualization adapts to individual reading preferences and automatically displays the current and prior studies, helping to save time and reduce cognitive load. User-defined AI prioritization provides the capability to bring critical findings to the top to ensure there is visibility.
“The future of enterprise imaging depends on connected, cloud-enabled solutions that improve access, collaboration, and efficiency. GE HealthCare is committed to helping providers unify imaging workflows and unlock deeper clinical insights through cloud and AI-enabled innovation,” said Scott Miller, CEO, Solutions for Enterprise Imaging, GE HealthCare.
Intelerad, a GE HealthCare company, will also be demonstrating its cloud-first solutions including InteleShare™. InteleShare is a cloud-based medical image exchange platform designed to accelerate patient care through seamless, secure access to imaging across complex, multi-facility healthcare environments worldwide. With native EHR integration and automated workflows, InteleShare helps healthcare organizations reduce administrative burden, improve patient and clinician experiences, and make better use of their existing technology investments.
Visit here to learn more about GE HealthCare and Intelerad solutions. GE HealthCare is at booth #313 and Intelerad is at booth #305.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.
1 https://www.acr.org/Clinical-Resources/Publications-and-Research/ACR-Bulletin/2026/radiologist-shortage-work-force-update
2 Available only for USA and UK. Genesis Radiology consists of Genesis View, Workflow Manager, Enterprise Archive.
